ANO1 and neoplasm: Furthermore, we realized that talabostat augmented immunotherapy in CT26 CDX, while the triple‐combination of ANO1 knockdown/anti‐PD‐1 antibody/FAP inhibitor maximized anti‐tumor effectiveness comparably with the double‐combination of ANO1 knockdown/FAP inhibitor or the double‐combination of ANO1 knockdown/anti‐PD‐1 antibody (Figure 8U).